Oil-based emulsion vaccine adjuvants

Current Protocols in Immunology

Volumn 2014, Issue , 2014, Pages 2.18.1-2.18.7

  Schijns, Virgil E J C ^a,b,c   Strioga, Marius ^d   Ascarateil, Stephane ^e  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b Epitopoietic Research Corporation (ERC)   (Belgium)

^c ERC   (Netherlands)

^d VILNIUS UNIVERSITY   (Lithuania)

^e SEPPIC   (France)

Author keywords

Adjuvants; emulsions; Vaccines

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLYSORBATE; SORBITAN ESTER; SORBITAN OLEATE; SORBITAN TRIOLEATE; VACCINE; ANTIGEN; EMULSION; OIL;

ARTICLE; DRUG FORMULATION; EMULSION; LIGHT SCATTERING; NEEDLE; PRIORITY JOURNAL; QUALITY CONTROL; SYRINGE; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; EMULSIONS; HUMANS; OILS; VACCINES;

EID: 84944446100     PISSN: 19343671     EISSN: 1934368X     Source Type: Journal    
DOI: 10.1002/0471142735.im0218s106     Document Type: Article

References (13)

1. Ascarateil, S. and Dupuis, S. 2006. Surfactants in vaccine adjuvants: Descriptions and perspectives. Vaccine 24:S283-S285
2. Dang, Y., Wagner, W.M., Gad, E., Rastetter, L., Berger, C.M., Holt, G.E., and Disis, M.L. 2012. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin. Cancer Res. 18:3122-3131.
3. Flemming, A. 2013. Tumour vaccination: Devil in the details of adjuvant choice. Nat. Rev. Drug Discov. 12:343.
4. Hailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M.A., Huang, X.F., Dorta-Estremera, S.M., Greeley, N.R., Nitti, G., Peng, W., Liu, C., Lou, Y., Wang, Z., Ma, W., Rabinovich, B., Schluns, K.S., Davis, R.E., Hwu, P., and Overwijk, W.W. 2013. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat. Med. 19:465-472.
5. Jansen, T., Hofmans, M.P.M., Theelen, M.J.G., and Schijns, V.E.J.C. 2005. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 23:1053-1060.
6. Jansen, T., Hofmans, M.P.M., Theelen, M.J.G., Manders, F., and Schijns, V.E.J.C. 2006. Structure-and oil type-based efficacy of emulsion adjuvants. Vaccine 24:5400-5405.
7. Koh, Y., Higgins, S.A., Weber, J.S., and Kast, W.M. 2006. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J. Transl. Med. 4:42.
8. Moreira, L.O., Smith, A.M., DeFreitas, A.A., Qualls, J.E., El Kasmi, K.C., and Murray, P.J. 2008. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 26:5808-5813.
9. Ott, G., Barchfeld, G.L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., and Van Nest, G. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:277-296.
10. Ramon, G. 1925. Sur l'aumentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet. 101:227-234.
11. Schijns, V.E.J.C. and Lavelle, E.C. 2011. Trends in vaccine adjuvants. Expert Rev. Vaccines 10:539-550.
12. Schijns, V.E.J.C. and O'Hagan, D. (Editors). 2006. Immunopotentiators in Modern Vaccines. Elsevier/Academic Press, London.
13. Schijns, V., Tartour, E., Michalek, J., Stathopoulos, A., Dobrovolskiene, N.T., and Strioga, M. 2014. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy 16:427-439.